Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
Drug reaction
Fulvestrant
Letrozole
Palbociclib
Skin rash
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
12
2020
accepted:
24
02
2021
pubmed:
9
3
2021
medline:
9
7
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
Treatment with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with letrozole or fulvestrant endocrine therapies. However, limited information exists on its cutaneous adverse effects (AE). Hence, we conducted a retrospective cohort study to investigate the prevalence and management of cutaneous AE during palbociclib and endocrine therapy. We included 324 adult patients with advanced breast cancer who received palbociclib between March 2016 and August 2020 within a tertiary comprehensive cancer centre. Patient demographics, details of previous and concurrent treatments, as well as treatment-related cutaneous AE were recorded from electronic records. The incidence of treatment-related cutaneous AE was 14.2% (46 from a total of 324 patients). The most frequent cutaneous reactions included maculopapular rash (41%), asteatosis (37%), pruritus and urticaria (20%), and bullous dermatitis reactions (9%). We identified two patients with treatment-induced subacute cutaneous lupus erythematosus, one case of bullous pemphigoid, and a single erythema multiforme. Patients received an average of 9 cycles of treatment, completing an average of 6 cycles before developing cutaneous AE, which persisted for a median of 43 days. Only 15% (n = 7) of affected patients required temporary suspension, and 4% (n = 2) required discontinuation. The majority were managed with potent topical steroids, with oral corticosteroids being required in 3 patients, and one patient required hydroxychloroquine. Our study describes both the spectrum of cutaneous AE of palbociclib and endocrine therapy, and approaches to management. Prompt management may limit the negative impact on patients, facilitating beneficial continuation of palbociclib and endocrine therapy.
Identifiants
pubmed: 33683521
doi: 10.1007/s10549-021-06169-9
pii: 10.1007/s10549-021-06169-9
doi:
Substances chimiques
Piperazines
0
Pyridines
0
Receptor, ErbB-2
EC 2.7.10.1
CDK4 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-545Références
Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive , Accessed [September 2019]
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35
doi: 10.1016/S1470-2045(14)71159-3
Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936
doi: 10.1056/NEJMoa1607303
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926–1936
doi: 10.1056/NEJMoa1810527
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H et al (2015) Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373(3):209–219
doi: 10.1056/NEJMoa1505270
CTCAE criteria: National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html [Accessed January 2020]
Pascual J, MacPherson IR, Armstrong AC, Ward SE, Parmar M, Turner AJ et al (2019) PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. JCO. 37(15):1051–1051
doi: 10.1200/JCO.2019.37.15_suppl.1051
Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 19(3):345–361
doi: 10.1007/s40257-017-0336-3
Damsky W, Kole L, Tomayko MM (2016) Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2:442–444
doi: 10.1016/j.jdcr.2016.05.009
Stavropoulos PG, Soura E, Antoniou C (2014) Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 28(9):1133–1140
doi: 10.1111/jdv.12366
Kanahara SM, Agrawal A (2016) Drug-induced bullous pemphigoid. J Gen Intern Med 31(11):1393–1394. https://doi.org/10.1007/s11606-016-3679-1
doi: 10.1007/s11606-016-3679-1
pubmed: 27067347
pmcid: 5071269
Chung VQ, Moschella SL, Zembowicz A, Liu V (2006) Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol 54:745
doi: 10.1016/j.jaad.2004.06.051
Wiznia LE, Subtil A, Choi JN (2013) Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol 149(9):1071–1075
doi: 10.1001/jamadermatol.2013.4957
Cleaver N, Ramirez J, Gildenberg S (2013) Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature. J Drugs Dermatol 12(9):1052–1055
pubmed: 24002156
Pinard J, Patel M, Granter SR, Vleugels RA, Merola JF (2018) Subacute cutaneous lupus erythematosus induced by palbociclib. J Cutan Med Surg 22(3):341–343
doi: 10.1177/1203475417752369
Freedman JB, Herskovitz I, Maderal AD (2019) Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. Int J Dermatol. https://doi.org/10.1111/ijd.14716
doi: 10.1111/ijd.14716
pubmed: 31724158
Calabrese G, Licata G, Gambardella A, De Rosa A, Ronchi A, Argenziano G (2020) A case of discoid lupus erythematosus because of palbociclib. J Cutan Pathol. https://doi.org/10.1111/cup.13696
doi: 10.1111/cup.13696
pubmed: 32222999
Wilkerson E, Hazey MA, Bahrami S, Callen JP (2012) Golimumab-Exacerbated Subacute Cutaneous Lupus Erythematosus. Arch Dermatol 148(10):1186–1190
doi: 10.1001/archdermatol.2012.1856
Furukawa F (1999) Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus. Histol Histopathol 14(2):627–633
pubmed: 10212823
Karagounis T, Vallurupalli M, Nathan N et al (2018) Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep 4(5):452–454
doi: 10.1016/j.jdcr.2017.12.015
Widmer S, Grossman M (2018) Chemotherapy patient with stevens-johnson syndrome presents to the emergency department: a case report. Am J Emerg Med 36(7):1325.e3-1325.e4
doi: 10.1016/j.ajem.2018.04.019
Santoro S, Santini M, Pepe C, Tognetti E, Cortelazzi C, Ficarelli E, De Panfilis G (2011) Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 25:596–598
doi: 10.1111/j.1468-3083.2010.03803.x
Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol. 35(5):797
pubmed: 18381791